North America Orthobiologics Market Outlook to 2020

News provided by

Mar 20, 2014, 09:24 ET

NEW YORK, March 20, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

North America Orthobiologics Market Outlook to 2020
http://www.reportlinker.com/p02051499/North-America-Orthobiologics-Market-Outlook-to-2020.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic

Summary

GlobalData's new report, "North America Orthobiologics Market Outlook to 2020", provides key market data on the North America Orthobiologics market. The report provides value, in millions of US dollars, and volume (in units) and average price data (in US dollars), within market categories – Bone Graft Substitutes, Viscosupplementation, Bone Allografts and Bone Growth Stimulators.

The report also provides company shares and distribution shares data for each of these market categories, and global corporate-level profiles of the key market participants, pipeline products, and news and deals related to the Orthobiologics market wherever available.

The data in the report is derived from dynamic market forecast models. GlobalData uses epidemiology and capital equipment–based models to estimate and forecast the market size. The objective is to provide information that represents the most up-to-date data of the industry possible.

The epidemiology-based forecasting model makes use of epidemiology data gathered from research publications and primary interviews with physicians to establish the target patient population and treatment flow patterns for individual diseases and therapies. Using prevalence and incidence data and diagnosed and treated population, the epidemiology-based forecasting model arrives at the final numbers.

Capital equipment–based forecasting models are done based on the installed base, replacements and new sales of a specific device/equipment in healthcare facilities such as hospitals, clinics and diagnostic centers. Data for average number of units per facility is used to arrive at the installed base of the capital equipment. Sales for a particular year are arrived at by calculating the replacement units and new units (additional and first-time purchases).

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

- Market size for Orthobiologics market categories – Bone Graft Substitutes, Viscosupplementation, Bone Allografts and Bone Growth Stimulators.
- Annualized market revenues (USD million), volume (units) and average selling price ($) data for each of the market categories. Data is provided from 2005 to 2012 and forecast to 2020.
- 2012 company shares and distribution shares data for each of the market categories.
- Global corporate-level profiles of key companies operating within the North America Orthobiologics market.
- Key players covered include DePuy Companies, Sanofi, Medtronic, Inc., NuVasive, Inc., Biomet, Inc., Smith & Nephew Plc, Baxter International Inc., Wright Medical Group, Inc., Stryker Corporation and Alphatec Holdings, Inc.

Reasons to buy

- Develop business strategies by identifying the key market segments poised for strong growth in the future.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the market.
- Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what's the most preferred mode of product distribution – Identify, understand and capitalize.
1 Table of Contents
2 Introduction 11
2.1 What Is This Report About? 11
2.2 Orthobiologics Market Segmentation 11
2.3 Definitions of Markets Covered in the Report 12
3 Orthobiologics Market, North America 13
3.1 Orthobiologics Market, North America, Revenue ($m), 2005-2020 13
3.2 Orthobiologics Market, North America, Category Comparison by Revenue ($m), 2005-2020 15
3.3 Orthobiologics Market, North America, Revenue ($m), 2005-2012 17
3.4 Orthobiologics Market, North America, Revenue ($m), 2012-2020 19
3.5 Orthobiologics Market, North America, Volume (Units), 2005-2020 21
3.6 Orthobiologics Market, North America, Volume (Units), 2005-2012 23

3.7 Orthobiologics Market, North America, Volume (Units), 2012-2020 25
3.8 Orthobiologics Market, North America, Company Share by Revenue ($m), 2011-2012 27
4 Orthobiologics Market, Canada 29
4.1 Orthobiologics Market, Canada, Revenue ($m), 2005-2012 29
4.2 Orthobiologics Market, Canada, Revenue ($m), 2012-2020 31
4.2.1 Bone Graft Substitutes Market, Canada, Revenue ($m), by Segment, 2005-2012 33
4.2.2 Bone Graft Substitutes Market, Canada, Revenue ($m), by Segment, 2012-2020 35
4.3 Orthobiologics Market, Canada, Volume (Units), 2005-2012 37
4.4 Orthobiologics Market, Canada, Volume (Units), 2012-2020 39
4.4.1 Bone Graft Substitutes Market, Canada, Volume (Units), by Segment, 2005-2012 41
4.4.2 Bone Graft Substitutes Market, Canada, Volume (Units), by Segment, 2012-2020 43
4.5 Orthobiologics Market, Canada, Average Price ($), 2005-2020 45
4.6 Orthobiologics Market, Canada, Distribution Share by Revenue ($m), 2011-2012 47
4.7 Orthobiologics Market, Canada, Company Share by Revenue ($m), 2011-2012 48
5 Orthobiologics Market, Mexico 50
5.1 Orthobiologics Market, Mexico, Revenue ($m), 2005-2012 50
5.2 Orthobiologics Market, Mexico, Revenue ($m), 2012-2020 52
5.2.1 Bone Graft Substitutes Market, Mexico, Revenue ($m), by Segment, 2005-2012 54
5.2.2 Bone Graft Substitutes Market, Mexico, Revenue ($m), by Segment, 2012-2020 56
5.3 Orthobiologics Market, Mexico, Volume (Units), 2005-2012 58
5.4 Orthobiologics Market, Mexico, Volume (Units), 2012-2020 60
5.4.1 Bone Graft Substitutes Market, Mexico, Volume (Units), by Segment, 2005-2012 62
5.4.2 Bone Graft Substitutes Market, Mexico, Volume (Units), by Segment, 2012-2020 64
5.5 Orthobiologics Market, Mexico, Average Price ($), 2005-2020 66
5.6 Orthobiologics Market, Mexico, Distribution Share by Revenue ($m), 2011-2012 68
5.7 Orthobiologics Market, Mexico, Company Share by Revenue ($m), 2011-2012 69
6 Orthobiologics Market, United States 71

6.1 Orthobiologics Market, United States, Revenue ($m), 2005-2012 71
6.2 Orthobiologics Market, United States, Revenue ($m), 2012-2020 73
6.2.1 Bone Graft Substitutes Market, United States, Revenue ($m), by Segment, 2005-2012 75
6.2.2 Bone Graft Substitutes Market, United States, Revenue ($m), by Segment, 2012-2020 77
6.3 Orthobiologics Market, United States, Volume (Units), 2005-2012 79
6.4 Orthobiologics Market, United States, Volume (Units), 2012-2020 81
6.4.1 Bone Graft Substitutes Market, United States, Volume (Units), by Segment, 2005-2012 83
6.4.2 Bone Graft Substitutes Market, United States, Volume (Units), by Segment, 2012-2020 85
6.5 Orthobiologics Market, United States, Average Price ($), 2005-2020 87
6.6 Orthobiologics Market, United States, Distribution Share by Revenue ($m), 2011-2012 89
6.7 Orthobiologics Market, United States, Company Share by Revenue ($m), 2011-2012 90
7 Overview of Key Companies in North America Orthobiologics Market 92
7.1 Medtronic, Inc. 92
7.1.1 Company Overview 92
7.2 DePuy Companies 92
7.2.1 Company Overview 92
7.3 Sanofi 92
7.3.1 Company Overview 92
7.4 Globus Medical, Inc. 93
7.4.1 Company Overview 93
7.5 NuVasive, Inc. 93
7.5.1 Company Overview 93
7.6 Stryker Corporation 94
7.6.1 Company Overview 94
7.7 Biomet, Inc. 94
7.7.1 Company Overview 94
7.8 DJO Finance LLC 94
7.8.1 Company Overview 94
7.9 Baxter International Inc. 95
7.9.1 Company Overview 95
7.10 Smith & Nephew Plc 95
7.10.1 Company Overview 95

7.11 Wright Medical Group, Inc. 95
7.11.1 Company Overview 95
7.12 Anika Therapeutics, Inc. 96
7.12.1 Company Overview 96
7.13 Seikagaku Corporation 96
7.13.1 Company Overview 96
7.14 Orthofix International N.V. 97
7.14.1 Company Overview 97
8 Orthobiologics Market Pipeline Products 98
9 Financial Deals Landscape 102
9.1 Asset Transactions 102
9.1.1 Biomet Completes Acquisition Of Trauma Business Of Depuy Orthopaedics For US$280 Million 102
9.2 Partnerships 104
9.2.1 Artimplant Enters Into Co-Marketing Agreement With Tiller International Capital 104
10 Recent Developments 105
10.1 Corporate Communications 105
10.1.1 Jan 09, 2014: ISTO Technologies names George W. Dunbar, Jr. President and Chief Executive Officer 105
10.1.2 Jan 07, 2014: ISTO Technologies Appoints James McGorry to Board of Directors 106
10.1.3 Jan 02, 2014: Alphatec Spine Announces Executive Leadership Changes 106
10.1.4 Jan 02, 2014: Alphatec Spine Announces Executive Leadership Changes 107
10.1.5 Nov 14, 2013: Histogenics announces appointment of John H. Johnson to its board of directors 108
10.1.6 Oct 28, 2013: Histogenics Announces Nancy Lynch, M.D., as CMO 108
10.1.7 Oct 14, 2013: Exactech Names Orthopaedic Executive Bill Shopoff as Vice President U.S. Sales; Industry Veteran Bob Purcell Retires After 40+ Years in Healthcare 109
10.1.8 Sep 25, 2013: Accellent Announces the Promotion of Jeremy Friedman to President and Chief Operating Officer for the Cardio & Vascular Business and the Appointment of Richard Johnson as Interim CFO 109

10.1.9 Aug 27, 2013: Integra LifeSciences Appoints Donald E. Morel, Jr., Ph.D. as a Director and Announces Retirement of Neal Moszkowski as a Director 110
10.1.10 Aug 20, 2013: Histogenics Announces Key Additions to Management Team 110
10.1.11 Jul 23, 2013: Dean Schauer, Executive Vice President, Cardio & Vascular Group, Announces Resignation 111
10.1.12 Jun 10, 2013: Histogenics Appoints Peter Greenleaf As CEO 111
10.1.13 May 16, 2013: Cerapedics Announces Senior Management Changes 112
10.1.14 Mar 18, 2013: Integra LifeSciences Holdings Corporation Announces Changes to Its Board of Directors 113
10.2 Financial Announcements 114
10.2.1 Feb 19, 2014: Exactech 2013 Revenue Up 6% to $237.1M, Net Income Up 21% to $15.4M, EPS $1.12 114
10.2.2 Feb 18, 2014: Medtronic Reports Third Quarter Earnings 115
10.2.3 Jan 30, 2014: Bard Announces Fourth Quarter Results 117
10.2.4 Jan 22, 2014: BIOTRONIK Enrolls First Patients in Expansion of ProMRI Clinical Trial 117
10.2.5 Dec 23, 2013: Titan Pharmaceuticals Receives Official Minutes From FDA Meeting on Probuphine New Drug Application 119
10.2.6 Dec 11, 2013: Bard Declares Quarterly Dividend 120
10.2.7 Nov 19, 2013: Medtronic Reports Second Quarter Earnings 120
10.2.8 Nov 11, 2013: Medtronic to Announce Financial Results for Its Second Quarter of Fiscal Year 2014 122
10.2.9 Nov 07, 2013: Accellent Announces Third Quarter 2013 Results 123
10.2.10 Nov 04, 2013: Wright Medical Group Reports 2013 Third Quarter Financial Results 124
10.2.11 Oct 28, 2013: Integra LifeSciences Reports Third Quarter 2013 Financial Results 126
10.2.12 Oct 23, 2013: Exactech Q3 Net Income up 25% to $3.2 Million; Diluted EPS $0.23 vs. $0.19; Worldwide Sales Up 9% to $55.7 Million; U.S. Sales Increased 11% 127
10.2.13 Oct 22, 2013: Bard Announces Third Quarter Results 128
10.2.14 Oct 11, 2013: Integra LifeSciences to Host Its Third Quarter 2013 Earnings Results Conference Call on October 28, 2013 128
10.2.15 Oct 09, 2013: Bard Declares Quarterly Dividend 129
10.2.16 Oct 08, 2013: Exactech Schedules Third Quarter 2013 Earnings Release and Conference Call 129
10.2.17 Oct 03, 2013: Wright Medical Group to Host Third Quarter 2013 Earnings Conference Call 129

10.2.18 Oct 01, 2013: Bard to Host Earnings Conference Call on October 22, 2013 129
10.2.19 Sep 18, 2013: Avo Photonics Provides Design and Production Services for Optofluidics' NanoTweezer System 129
10.2.20 Sep 09, 2013: ICU Medical's New ChemoLock Needlefree Closed System Transfer Device Receives First-Ever FDA 510(k) Clearances for Both Pharmacy and Patient Administration Applications 130
10.2.21 Aug 22, 2013: Douglasville Nursing and Rehabilitation Center Installs Masimo Patient SafetyNet System for Improved Patient Monitoring 131
10.2.22 Aug 20, 2013: Medtronic Reports First Quarter Earnings 132
10.2.23 Aug 13, 2013: Accellent Announces Second Quarter 2013 Results 133
10.2.24 Aug 12, 2013: Medtronic to Announce Financial Results for Its First Quarter of Fiscal Year 2014 135
10.2.25 Aug 06, 2013: Accellent Announces Timing of Second Quarter 2013 Earnings Release and Conference Call 135
10.2.26 Aug 05, 2013: Wright Medical Group Reports 2013 Second Quarter Financial Results 135
10.2.27 Aug 01, 2013: Integra LifeSciences Reports Second Quarter 2013 Financial Results 137
10.2.28 Jul 24, 2013: Bard Announces Second Quarter Results 138
10.2.29 Jul 24, 2013: Exactech Q2 Net Income up 23% to $3.7 Million. Diluted EPS $0.27 vs. $0.23. Worldwide Sales Up 10% to $60.6 Million. U.S. Sales Increased 13% 138
10.2.30 Jul 10, 2013: Exactech Schedules Second Quarter 2013 Earnings Release and Conference Call 139
10.2.31 Jul 10, 2013: Wright Medical Group, Inc. to Host Second Quarter 2013 Earnings Conference Call 140
10.2.32 Jul 03, 2013: Integra LifeSciences to Host Its Second Quarter 2013 Earnings Results Conference Call on August 1, 2013 140
10.2.33 Jun 14, 2013: Atossa Genetics And HealthSmart Sign Nationwide Agreement For ForeCYTE Breast Health Test 140
10.2.34 Jun 04, 2013: Neuros Medical Announces Pilot Study Results On Electrical Nerve Block Technology 142
10.2.35 May 30, 2013: DiFusion Completes Series Of In Vitro Tests And An In Vivo Study To Validate Efficacy Of Its CleanFuze 142

10.2.36 May 21, 2013: Medtronic Reports Revenue Of $16.6 Billion In Fiscal 2013 143
10.2.37 May 14, 2013: Accellent Reports Revenue Of $120.8m In Q1 2013 145
10.2.38 Apr 30, 2013: Wright Medical Reports Revenue Of $120.4m In Q1 2013 145
10.2.39 Apr 23, 2013: Exactech Reports Revenue Of $59.3m In Q1 2013 147
10.2.40 Apr 16, 2013: Exactech Schedules First Quarter 2013 Earnings Release and Conference Call 147
10.2.41 Apr 10, 2013: Integra LifeSciences to Host Its First Quarter 2013 Earnings Results Conference Call on May 2, 2013 148
10.2.42 Mar 27, 2013: Accellent Reports Revenue Of $498.6m In 2012 148
10.2.43 Feb 26, 2013: Exactech Reports Revenue Of $224.3m In 2012 148
10.3 Government and Public Interest 149
10.3.1 Jan 06, 2014: Medtronic CEO Omar Ishrak to Speak at J.P. Morgan Healthcare Conference 149
10.3.2 Jan 06, 2014: Bard to Host Earnings Conference Call on January 30, 2014 150
10.3.3 Dec 30, 2013: Integra LifeSciences to Participate in the 32nd Annual J.P. Morgan Healthcare Conference 150
10.3.4 Dec 20, 2013: Bard to Present at J.P. Morgan Healthcare Conference 150
10.3.5 Dec 18, 2013: Wright Medical Group to Participate in 32nd Annual J.P. Morgan Healthcare Conference 150
10.3.6 Dec 04, 2013: Medtronic CFO Gary Ellis to Speak at Oppenheimer Healthcare Conference 150
10.3.7 Nov 26, 2013: ISTO To Present At Upcoming Conferences 150
10.3.8 Nov 26, 2013: Medtronic EVP & President Mike Coyle to Speak at Piper Jaffray Healthcare Conference 151
10.3.9 Nov 20, 2013: Bard to Present at Piper Jaffray Healthcare Conference 151
10.3.10 Nov 18, 2013: Integra LifeSciences to Participate in the Piper Jaffray Healthcare and Oppenheimer Healthcare Conferences in December 151
10.3.11 Nov 12, 2013: Wright Medical Group to Participate in 25th Annual Piper Jaffray Healthcare Conference 151
10.3.12 Oct 29, 2013: Bard to Present at Credit Suisse Healthcare Conference 151
10.3.13 Oct 28, 2013: Wright Medical to Participate in Credit Suisse 2013 Healthcare Conference 152
10.3.14 Sep 10, 2013: Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th 152

10.3.15 Sep 06, 2013: Medtronic CFO Gary Ellis to Speak at Morgan Stanley Healthcare Conference 152
10.3.16 Sep 03, 2013: Bard to Host Conference Call on September 4, 2013 152
10.3.17 Aug 29, 2013: Integra LifeSciences to Participate in Investor Conferences in September 152
10.3.18 Aug 21, 2013: Wright Medical Group to Participate in Baird 2013 Health Care Conference 152
10.3.19 Aug 20, 2013: Bard to Present at Morgan Stanley Global Healthcare Conference 153
10.3.20 Aug 20, 2013: Wright Medical Group to Participate in Morgan Stanley Global Healthcare Conference 153
10.3.21 Aug 06, 2013: Exactech Announces Investor Presentation at Canaccord Genuity Growth Conference 153
10.3.22 May 29, 2013: Integra LifeSciences to Participate in Investor Conferences in June 153
10.3.23 May 07, 2013: Integra LifeSciences to Participate in Investor Conferences in May 154
10.3.24 Mar 05, 2013: Integra LifeSciences to Participate in Investor Conferences in March 154
10.4 Legal And Regulatory 154
10.4.1 Feb 11, 2014: Alphatec Spine Announces Jury Verdict in the OrthoTec Litigation 154
10.4.2 Jan 28, 2014: 3-D Matrix Files Patent Infringement Complaint Against Menicon and B-Bridge International 155
10.4.3 Jan 22, 2014: Medtronic Statement on U.S. Supreme Court Ruling in Medtronic, Inc. v. Mirowski Family Ventures 155
10.4.4 Oct 19, 2013: Medtronic Statement on Medical Device Security 156
10.4.5 Sep 26, 2013: Integra LifeSciences Announces Resolution of Warning Letter Related to Its Plainsboro, NJ, Manufacturing Facility 156
10.4.6 Aug 01, 2013: Medtronic Notifies More Than 2,700 Patients Of Lost Records 157
10.4.7 Jul 01, 2013: Bronstein, Gewirtz & Grossman, LLC Announces that a Securities Class Action has been Filed Against Medtronic, Inc. 157
10.5 Other Significant Developments 157
10.5.1 Feb 13, 2014: Medtronic Announces Cash Dividend for Fourth Quarter of Fiscal Year 2014 157
10.5.2 Jan 28, 2014: Medtronic Relocates Its Regional Headquarters to Dubai 158
10.5.3 Dec 16, 2013: Genzyme and NORD Establish Program to Help Undiagnosed Patients with Rare Diseases 159
10.5.4 Dec 09, 2013: Launch of NuCollagen to Supply Laboratory and Medical Grade Bovine Collagen 159
10.5.5 Dec 04, 2013: Medtronic Issues $500,000 in Health Access Grants to Support Diabetes Services for the Underserved of Greater Los Angeles 160

10.5.6 Oct 23, 2013: Integra LifeSciences Announces Update on Optimization Initiatives 161
10.5.7 Aug 22, 2013: Medtronic Announces Cash Dividend for Second Quarter of Fiscal Year 2014 162
10.5.8 Aug 12, 2013: Small Bone Innovations Launches New Charcot Solution Website 162
10.6 Product News 163
10.6.1 Dec 05, 2013: Physicians Discover New Knee Ligament 163
10.6.2 Nov 15, 2013: FDA Classifies Medtronic's Worldwide Voluntary Field Action on Guidewires as Class I Recall 164
10.6.3 Sep 23, 2013: Vista Equity Partners Completes Acquisition Of Majority Interest In Greenway Medical Technologies For US$555.3 Million In Going Private Transaction 164
10.6.4 May 23, 2013: RTI Biologics Passes Five Million Mark In Distributing Implants Sterilized With Zero Incidence Of Implant Associated Infection 166
10.6.5 Apr 29, 2013: Advanced Biologics Adds More Patient Results Showcasing OsteoAMP's Superior Fusion Rates Compared To rhBMP-2 167
10.6.6 Mar 19, 2013: Ranier Technology Gets US Patent For Graduated Modulus Technology 167
10.7 Strategy And Business Planning 168
10.7.1 Sep 17, 2013: Medtronic Opens New Customer Innovation Centre in Galway, Ireland 168
10.7.2 Sep 02, 2013: Medtronic announces formation of hospital solutions business aimed at driving efficiencies 168
10.7.3 Aug 29, 2013: Medtronic To Set Up Global Center Of Excellence In Singapore For Business Model Innovation 170
11 Appendix 171
11.1 Research Methodology 172
11.1.1 Coverage 172
11.1.2 Secondary Research 172
11.1.3 Primary Research 173
11.1.4 Market Modeling and Forecasting 174
11.1.5 Company Share Analysis 177
11.1.6 Distribution Share Analysis 178
11.2 Expert Panel 179
11.3 GlobalData Consulting 179
11.4 Contact Us 179
11.5 Disclaimer 179

1.1 List of Tables
Table 1: Orthobiologics Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2005-2020 14
Table 2: Orthobiologics Market, North America, Category Comparison by Revenue ($m), USD Constant, 2005-2020 16
Table 3: Orthobiologics Market, North America, Revenue ($m), Historic, USD Constant, 2005-2012 18
Table 4: Orthobiologics Market, North America, Revenue ($m), Forecast, USD Constant, 2012-2020 20
Table 5: Orthobiologics Market, North America, Volume (Units), 2005-2020 22
Table 6: Orthobiologics Market, North America, Volume (Units), Historic, 2005-2012 24
Table 7: Orthobiologics Market, North America, Volume (Units), Forecast, 2012-2020 26
Table 8: Orthobiologics Market, North America, Company Share by Revenue ($m), USD Constant, 2011-2012 28
Table 9: Orthobiologics Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 30
Table 10: Orthobiologics Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 32
Table 11: Bone Graft Substitutes Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 34
Table 12: Bone Graft Substitutes Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 36
Table 13: Orthobiologics Market, Canada, Volume (Units), Historic, 2005-2012 38
Table 14: Orthobiologics Market, Canada, Volume (Units), Forecast, 2012-2020 40
Table 15: Bone Graft Substitutes Market, Canada, Volume (Units), Historic, 2005-2012 42
Table 16: Bone Graft Substitutes Market, Canada, Volume (Units), Forecast, 2012-2020 44
Table 17: Orthobiologics Market, Canada, Average Price ($), Historic, 2005-2012 45
Table 18: Orthobiologics Market, Canada, Average Price ($), Forecast, 2012-2020 46
Table 19: Orthobiologics Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2011-2012 47
Table 20: Orthobiologics Market, Canada, Company Share by Revenue ($m), USD Constant, 2011-2012 49
Table 21: Orthobiologics Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 51
Table 22: Orthobiologics Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 53
Table 23: Bone Graft Substitutes Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 55
Table 24: Bone Graft Substitutes Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 57
Table 25: Orthobiologics Market, Mexico, Volume (Units), Historic, 2005-2012 59
Table 26: Orthobiologics Market, Mexico, Volume (Units), Forecast, 2012-2020 61

Table 27: Bone Graft Substitutes Market, Mexico, Volume (Units), Historic, 2005-2012 63
Table 28: Bone Graft Substitutes Market, Mexico, Volume (Units), Forecast, 2012-2020 65
Table 29: Orthobiologics Market, Mexico, Average Price ($), Historic, 2005-2012 66
Table 30: Orthobiologics Market, Mexico, Average Price ($), Forecast, 2012-2020 67
Table 31: Orthobiologics Market, Mexico, Distribution Share by Revenue ($m), USD Constant, 2011-2012 68
Table 32: Orthobiologics Market, Mexico, Company Share by Revenue ($m), USD Constant, 2011-2012 70
Table 33: Orthobiologics Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 72
Table 34: Orthobiologics Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 74
Table 35: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 76
Table 36: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 78
Table 37: Orthobiologics Market, United States, Volume (Units), Historic, 2005-2012 80
Table 38: Orthobiologics Market, United States, Volume (Units), Forecast, 2012-2020 82
Table 39: Bone Graft Substitutes Market, United States, Volume (Units), Historic, 2005-2012 84
Table 40: Bone Graft Substitutes Market, United States, Volume (Units), Forecast, 2012-2020 86
Table 41: Orthobiologics Market, United States, Average Price ($), Historic, 2005-2012 87
Table 42: Orthobiologics Market, United States, Average Price ($), Forecast, 2012-2020 88
Table 43: Orthobiologics Market, United States, Distribution Share by Revenue ($m), USD Constant, 2011-2012 89
Table 44: Orthobiologics Market, United States, Company Share by Revenue ($m), USD Constant, 2011-2012 91
Table 45: Orthobiologics Market Pipeline Products 98
Table 46: Biomet Completes Acquisition Of Trauma Business Of Depuy Orthopaedics For US$280 Million 102
Table 47: Artimplant Enters Into Co-Marketing Agreement With Tiller International Capital 104
Table 48: Total Number of Primary Research Participants, Orthopedic Devices Market, by Country 174

1.2 List of Figures
Figure 1: Orthobiologics Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2005-2020 13
Figure 2: Orthobiologics Market, North America, Category Comparison by Revenue ($m), USD Constant, 2005-2020 15
Figure 3: Orthobiologics Market, North America, Revenue ($m), Historic, USD Constant, 2005-2012 17
Figure 4: Orthobiologics Market, North America, Revenue ($m), Forecast, USD Constant, 2012-2020 19

Figure 5: Orthobiologics Market, North America, Volume (Units), 2005-2020 21
Figure 6: Orthobiologics Market, North America, Volume (Units), Historic, 2005-2012 23
Figure 7: Orthobiologics Market, North America, Volume (Units), Forecast, 2012-2020 25
Figure 8: Orthobiologics Market, North America, Company Share (%), 2012 27
Figure 9: Orthobiologics Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 29
Figure 10: Orthobiologics Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 31
Figure 11: Bone Graft Substitutes Market, Canada, Revenue ($m), USD Constant, Historic, 2005-2012 33
Figure 12: Bone Graft Substitutes Market, Canada, Revenue ($m), USD Constant, Forecast, 2012-2020 35
Figure 13: Orthobiologics Market, Canada, Volume (Units), Historic, 2005-2012 37
Figure 14: Orthobiologics Market, Canada, Volume (Units), Forecast, 2012-2020 39
Figure 15: Bone Graft Substitutes Market, Canada, Volume (Units), Historic, 2005-2012 41
Figure 16: Bone Graft Substitutes Market, Canada, Volume (Units), Forecast, 2012-2020 43
Figure 17: Orthobiologics Market, Canada, Company Share (%), 2012 48
Figure 18: Orthobiologics Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 50
Figure 19: Orthobiologics Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 52
Figure 20: Bone Graft Substitutes Market, Mexico, Revenue ($m), USD Constant, Historic, 2005-2012 54
Figure 21: Bone Graft Substitutes Market, Mexico, Revenue ($m), USD Constant, Forecast, 2012-2020 56

Figure 22: Orthobiologics Market, Mexico, Volume (Units), Historic, 2005-2012 58
Figure 23: Orthobiologics Market, Mexico, Volume (Units), Forecast, 2012-2020 60
Figure 24: Bone Graft Substitutes Market, Mexico, Volume (Units), Historic, 2005-2012 62
Figure 25: Bone Graft Substitutes Market, Mexico, Volume (Units), Forecast, 2012-2020 64
Figure 26: Orthobiologics Market, Mexico, Company Share (%), 2012 69
Figure 27: Orthobiologics Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 71
Figure 28: Orthobiologics Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 73
Figure 29: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Historic, 2005-2012 75
Figure 30: Bone Graft Substitutes Market, United States, Revenue ($m), USD Constant, Forecast, 2012-2020 77
Figure 31: Orthobiologics Market, United States, Volume (Units), Historic, 2005-2012 79
Figure 32: Orthobiologics Market, United States, Volume (Units), Forecast, 2012-2020 81
Figure 33: Bone Graft Substitutes Market, United States, Volume (Units), Historic, 2005-2012 83
Figure 34: Bone Graft Substitutes Market, United States, Volume (Units), Forecast, 2012-2020 85
Figure 35: Orthobiologics Market, United States, Company Share (%), 2012 90
Figure 36: GlobalData Epidemiology-Based Forecasting Model 176
Figure 37: GlobalData Capital Equipment-Based Forecasting Model 177
Figure 38: Primary Interviews by Participant Type (%) 178